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ABSTRACT 
The present study aimed to investigate the effects of leptin and ghrelin on pulsatile pulsatile gonadotrophin-
releasing hormone (GnRH) secretion in vitro with emphasis on neuropeptide mediators and changes between 
prepuberty (15 days) and sexual maturity (50 days) in the male rat. When hypothalamic expiants were studied 90 
min after an intraperitoneal injection of leptin, ghrelin or agouti-related protein (AgRP) at 15 days, the GnRH 
interpulse interval (IPI) was significantly increased by ghrelin and AgRP and decreased by leptin. At 50 days, an 
increase in GnRH IPI was also caused by ghrelin and AgRP. When the peptides were directly incubated with the 
expiants, the effects of leptin and AgRP in vitro were consistent with those seen after in vivo administration. By 
contrast, ghrelin resulted in a reduction of GnRH IPI and this was observed at 15 days only. To delineate the 
neuropeptide mediators of leptin and the effects of ghrelin in the hypothalamus, various hypothalamic 
neuropeptides and antagonists were used in vitro. At 15 days, the GnRH IPI was significantly decreased after 
incubation with cocaine and amphetamine-regulated transcript (CART), α-melanocyte-stimulating hormone, 
corticotrophin-releasing factor (CRF) and neuropeptide Y (NPY). The reduction of GnRH IPI caused by leptin 
was partially prevented by either an anti-CART antiserum or SHU 9119, a melanocortin MC3/MC4 receptor 
antagonist or a CRF receptor antagonist. The NPY-Y5 receptor antagonist did not influence the effects of leptin 
whereas that antagonist totally prevented the decrease in GnRH IPI caused by ghrelin. The ghrelin-induced 
reduction of GnRH IPI was partially prevented by SHU 9119. When used alone, SHU 9119 or a CRF-receptor 
antagonist resulted in increased GnRH IPI at 50 days while they had no effects at 15 days. The NPY-Y5 receptor 
antagonist resulted in increased GnRH IPI at 15 and 50 days. In conclusion, leptin and ghrelin show opposing 
effects on pulsatile GnRH secretion after administration in vivo whereas they both have stimulatory effects in 
vitro. Such effects involve consistently the anorectic peptides CART and CRF for leptin that are mainly active at 
15 days. The melanocortigenic system appears to mediate the effects of both leptin and ghrelin. The effects of 
ghrelin also involve NPY receptors and operate effectively before and at sexual maturity. 
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In the hypothalamus, the control of energy balance is tightly regulated through complex interactions between 
peripheral nutrition-related hormones and hypothalamic neuropeptides (1, 2). Several decades ago, a link 
between fat mass and menstrual cyclicity already suggested that nutrition-related hormones could influence the 
hypothalamic control of puberty and reproduction (3). Further insight came from isolation of leptin, an 
adipocyte-derived anorectic hormone involved in the regulation of body weight, as well as a facilitatory or 
permissive control of puberty and reproduction (4, 5). We have previously shown that leptin incubation with 
prepubertal rat hypothalamic expiants could directly accelerate the pulsatile gonadotrophin-releasing hormone 
(GnRH) secretion (6). In addition, the effects of leptin in vitro on pulsatile GnRH secretion showed 
developmental changes because they disappeared with sexual maturation, except for an increased amplitude of 
GnRH pulses in the adult cycling female hypothalamus (7). More recently, ghrelin was isolated as an orexigenic 
peptide secreted by stomach cells (8, 9). Ghrelin was shown to be also expressed in hypothalamic neurones, 
providing an anatomical basis for local connection with central regulation of energy homeostasis (10). Ghrelin 
was shown to inhibit luteinising hormone (LH) secretion in adult individuals of different species (11-13) and to 
delay balano-preputial separation in the still maturing male rat (14). The first aim of the present study was to 
compare the effects of in vivo and in vitro administration of orexigenic and anorectic peptides on the interpulse 
interval (IPI) of GnRH secretion from hypothalamic expiants of prepubertal (15 days) and adult (50 days) male 
rats. Such a study was made possible by the availability of a model of hypothalamic expiant incubation where 
developmental variations in pulsatile GnRH secretion could be observed (15). 
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Several hypothalamic anorectic or orexigenic neuropeptides have emerged as possible mediators because they 
are stimulated or inhibited by leptin, respectively. Among the anorectic peptides, we have previously shown a 
partial mediatory role of cocaine and amphetamine-regulated transcript (CART) in the effects of leptin on 
pulsatile GnRH secretion (16). In rodents, the orexigenic effect of ghrelin could be mediated by the neuropeptide 
Y (NPY) and agouti-related protein (AgRP), which are colocalised in the arcuate nucleus (ARC) (17). We 
reported previously that NPY could accelerate the pulsatile GnRH secretion in vitro via the NPY Y5-receptor 
subtype and this effect was independent of leptin action (6). The second aim of the study was to study in vitro 
the interactions of leptin and ghrelin with different intrahypothalamic anorectic and orexigenic peptide 
mediators, in an attempt to elucidate the neuromedi-ating pathways involved in the control of pulsatile GnRH 
secretion. The studied neuropeptides were α-melanocyte-stimulating hormone (MSH), corticotrophin-releasing 
factor (CRF) and CART as anorectic mediators and NPY and AgRP as orexigenic mediators. Those mechanistic 
studies, based on the manipulation of neuropeptide-medi-ating pathways by the addition of agonists or 
antagonists in culture medium, were performed at 15 days because both leptin and ghrelin appeared to regulate 
GnRH secretion in vitro at that age. 
MATERIALS AND METHODS 
Animals and reagents 
Pregnants rats and male and female Wistar rats aged 15 and 50 days were purchased from the University of 
Liège and housed under standardised conditions (22 °C, 12 : 12 h light/dark cycle, lights on 06.30 h, food and 
water ad libitum). Prepubertal pups were with lactating mother until weaning, which was at 3 weeks of age. All 
experiments were carried out with the approval of the Belgium Ministry of Agriculture and the Ethical 
Committee at the University of Liège. 
The incubation medium MEM was purchased from Life Technology, Inc (Invitrogen Corporation, Merelbeke, 
Belgium). Anorectic peptides used were mouse recombinant leptin (R&D systems, Abingdon, UK), α-MSH 
(Sigma, St Louis, MO, USA), CRF (Phoenix Pharmaceuticals, Inc. Belmont, CA, USA) and CART(52-102)-
peptide (Novo Nordisk, Bagsvaerd, Denmark). Orexigenic peptides used were porcine NPY (Ferring 
Pharmaceutical Ltd, Copenhagen, Denmark), human AgRP (83-132)-NH2 (Phoenix Pharmaceuticals) and rat 
ghrelin (Neosystem, Strasbourg, France). The anti-CART antiserum was a kind gift from Novo Nordisk 
(Bagsvaerd, Denmark), SHU 9119, a pharmacological MC3/MC4 receptor antagonist was purchased from 
Bachem (Switzerland), and CRF antagonist, α-helical CRF 9-41 from Phoenix Pharmaceuticals, Inc. The NPY-
Y5 receptor antagonist, trans-naphthalene-1-sulphonic acid-4-{(4-(3-dimethylamino-propylamino)-quinazolin-2-
ylamino)-methyl}-aminde, was synthesised in the Medical Chemistry Department of Ferring Pharmaceutical 
Research Ltd (Chilworth, UK). 
Hypothalamic expiant incubation and GnRH radioimmunoasay (RIA) 
The animals were killed by decapitation between 10.00 h and 11.00 h. The retrochiasmatic hypothalamus was 
rapidly dissected and transferred into a static incubator as described previously (15). The medium consisted of 
phenol red free MEM supplemented with glucose, magnesium, glycine and bacitracin (25 mM, 1 mM, 10 nΜ, 20 
µΜ retrospectively). In each experiment, 12-15 expiants were studied individually for 4 h through collection and 
renewal of the incubation medium (0.5 ml) every 7.5 min. The samples were frozen until assayed. Each 
experiment included 12-15 hypothalamic expiants which were incubated individually, each in a separate 
chamber. GnRH was measured in duplicate using a highly sensitive RIA with intra-and interassay coefficient of 
14% and 18%, respectively (18). The GnRH antiserum was generously provided by Dr Y. F. Chen and V. D. 
Ramirez (Urbana, IL, USA) (19). The data below the limit of detection (5 pg/7.5 min) were assigned that value. 
Study protocols 
In vivo experiments 
Four groups of six rats aged 15 or 50 days and raised in similar conditions were studied. Leptin, ghrelin, AgRP 
or saline were injected intraperitoneally between 09.00 h and 09.20 h. The amounts injected were 30 µg/kg for 
leptin and 20 µg/kg for ghrelin and AgRP dissolved in 100 µ of 0.9% saline. These amounts were consistent with 
the lowest effective doses in dose-response feeding studies (20, 21). The animals were decapitated 90 min after 
peptide injection to study the retrochiasmatic expiants all in the same conditions (i.e. in the absence of any 
agonist or antagonist added in vitro). These comprised the ex vivo conditions. 
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In vitro experiments 
Using retrochiasmatic hypothalamic expiants obtained at 15 or 50 days, the frequency of pulsatile GnRH 
secretion was studied during incubation without (control) or with different substances. The studied anorectic 
peptides were leptin, CRF and α-MSH used at 10-7 M and CART (52-102) peptide used at 10-6 M. The orexigenic 
peptides ghrelin, AgRP and NPY were all used at 10-7 M. To antagonise specifically the different peptides or 
receptors, the anti-CART antiserum was used at 1 : 1000 dilution. The SHU 9199, the CRF antagonist and the 
NPY-Y5 receptor antagonist were used at 10-7 M. These antagonist effects in our conditions were investigated by 
studying the effect of anti-CART antiserum, SHU 9119 and a CRF antagonist, α-helical CRF 9-41 on the 
changes in pulsatile GnRH secretion induced by CART, α-MSH and CRF, respectively. 
To study the effects of leptin and ghrelin in vitro, as well as the effects of the antagonists on leptin and ghrelin-
induced changes in pulsatile GnRH frequency, the expiants were incubated in three different conditions: leptin or 
ghrelin alone, each antagonist alone and both reagents together. The different conditions (control, agonist, 
antagonist, agonist + antagonist) were applied throughout the entire expiant incubation period. 
Statistical analysis 
The occurrence of significant pulses of GnRH secretion was determined using the Pulsar programme as 
described previously (15). The mean ± SD interpulse interval was calculated. In some instances, all the expiants 
in a group showed a similar GnRH IPI. Then, SD was zero and could not be represented in the figures. 
Significant effect of treatment was determined by a t-test (control versus peptide). The effect of antagonists on 
control and treated group was determined by one-way ANOVA followed by Newman-Keuls post test when the 
threshold for significance of difference (P < 0.05) was reached. In previous studies between birth and puberty, 
we observed changes in GnRH pulse frequency without changes in amplitude (15). Only when using 
hypothalamic expiants from normally cycling adult female rats was an increase in amplitude of pulsatile GnRH 
secretion observed in the afternoon of pro-oestrous, and both leptin and NPY showed a stimulatory effect on the 
amplitude of GnRH secretion irrespective of the cycle phase (7). In this study, GnRH pulse amplitude was not 
significantly affected in any of the study conditions (data not shown). 
RESULTS 
As shown in Fig. 1(A), using hypothalamic expiants obtained 90 min after intraperitoneal administration of 
ghrelin or AgRP in 15-day-old rats, the mean ± SD GnRH IPI was significantly increased (73.8 ± 2.9 or 75 ± 3.2 
min, respectively) versus vehicle-injected groups (59.1 ± 2.5 min). Intraperitoneal injection of leptin in 15-day-
old rats resulted in a significant decrease of the GnRH IPI (45.5 ± 0 min). At 50 days (Fig. 1Β), similar effects 
were seen after intraperitoneal administration of ghrelin and AgRP but not after leptin. When the effects of the 
three peptides were directly studied in vitro during incubation with hypothalamic ex-plants (Fig. 1C,D), leptin 
caused a reduction of the GnRH IPI at 15 days and no change at 50 days. AgRP resulted in an increase in GnRH 
IPI which was significant at 50 days only (53.5 ± 2.7 min versus 39.2 ± 3.8 min in controls). As opposed to the 
effects after administration in vivo, expiant incubation with ghrelin in vitro caused a significant decrease in 
GnRH IPI at 15 days (50.2 ± 4.2 min). 
Table 1 show the mean ± SD GnRH IPI observed during incubation of hypothalamic expiants obtained in 15-
day-old male rats with different peptides and antagonists used alone or both together. When used alone, the 
studied antagonists did not change the GnRH IPI, except that the NPY-Y5 receptor antagonist caused a slight but 
significant increase in GnRH IPI. A significant reduction of the GnRH IPI was observed during incubation with 
the anorexigenic peptides CART, α-MSH and CRF, as well as the orexigenic peptide NPY. When each of the 
four peptides was coincubated together with its respective antagonist, the reduction in GnRH IPI was totally 
prevented (Table 1). The leptin-induced reduction in GnRH IPI (46.5 ± 2.8 min) was significantly but only 
partially overcome by anti-CART AS, SHU 9119 or CRF antagonist. As shown previously (6), the NPY-Y5 
receptor antagonist did not change the reduction in GnRH interpulse interval caused by leptin. The stimulatory 
ghrelin effect on GnRH IPI was not changed in the presence of anti-CART AS or CRF antagonist. By contrast, 
ghrelin effect was totally overcome by the NPY-Y5 receptor antagonist and partially by SHU 9119. Fig. 2 shows 
comparisons of the effects of expiant incubation with anorectic and orexigenic intrahypothalamic peptide 
mediators or their antagonists in prepubertal and adult male rats. Although all the studied peptides caused a 
reduction in GnRH IPI at 15 days, they did not show any effect at 50 days. As shown previously (6), a 
significant increase in GnRH IPI was observed during incubation with the NPY-Y5 receptor antagonist (10-6 M), 
both at 15 and 50 days. No effect was observed with the anti-CART AS at a 1 : 1000 dilution. The CRF 
antagonist and SHU9119 did not change the GnRH IPI at 15 days whereas they resulted in increased GnRH IPI 
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at 50 days. 
Fig. 1. Effects of in vivo administration and in vitro incubation of leptin, ghrelin, agouti-related protein (AgRP) 
and saline on the gonadotrophin-releasing hormone (GnRH) interpulse interval observed using hypothalamic 
expiants of 15- and 50-day-old male rats. In the ex vivo conditions, hypothalamic expiants were studied starting 
90 min after in vivo administration. *P < 0.05 versus control (saline). 
 
Table 1. Effects of Anorectic and Orexigenic Peptides and Antagonists on Gonadotrophin-Releasing Hormone 




(10 : 1000) 






No peptide 61.0 ± 2.2 (19) 60.7 ± 2.2 (4) 60.8 ± 2.5 (3) 61.5 ± 3.3 (4) 64.6 ± 3.8 (4)* 
CART 10-6 M 45.7 ± 2.7 (4)* 58.5 ± 3.0 (4) † - - - 
α-MSH 10-7 M 48.0 ± 3.8 (4)* - 60.0 ± 0.0 (4)† - - 
CRF 10-7 M 47.3 ± 3.4 (4)* - - 57.8 ± 3.7 (3)† - 
NPY 10-7 M 45.6 ± 2.3 (3)* - - - 60.5 ± 3.7 (5)† 
Leptin 10-7 M 46.5 ± 2.8 (11)* 56.3 ± 3.9 (4)* † 51.0 ± 4.3 (10)*† 54.0 ±2.9 (4)*† 46.50 ± 3.30 (5)* 
Ghrelin 10-7 M 50.3 ± 4.2 (7)* 49.5 ± 3.8 (6)* 56.3 ± 3.9 (4)*† 49.5 ± 3.8 (4)* 57.8 ± 3.5 (5)† 
Data are shown as the mean ± SD; the number of expiants is given between parentheses. *P < 0.05 vs no peptide and no antagonist; †P < 
0.05 vs no antagonist. CART, Cocaine and amphetamine-regulated transcript; α-MSH, α-melanocyte-stimulating hormone; corticotrophin-
releasing factor (CRF); NPY, neuropeptide Y. 
 
DISCUSSION 
In the present study, rat hypothalamic expiants are used because they retain in vitro the capacity to secrete GnRH 
in a reproducible pulsatile manner with developmental changes in GnRH pulse frequency between birth and 
adult age (15). This enabled the effects of leptin and ghrelin on pulsatile GnRH secretion and maturational 
changes to be studied directly. Although our previous data on the effects of leptin in vitro (6, 7) are consistent 
with the observations obtained in vivo by others (4, 5), the unexpected stimulatory effects of NPY that we 
obtained in vitro (6, 7) are discordant from the inhibitory effects reported in different conditions in vivo (22-24). 
Therefore, the effects of leptin and ghrelin have been compared after either in vivo administration or in vitro 
incubation with the peptides. After peripheral administration in vivo, the stimulatory effects of leptin and the 
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inhibitory effects of ghrelin on the GnRH pulse generator are consistent with the opposing effects of leptin and 
ghrelin on energy balance as well as on LH levels in different species (4, 5, 11-14). However, in vitro, ghrelin 
shows puzzling stimulatory effects on pulsatile GnRH secretion, which are in contradiction to our observations 
after in vivo administration. Because some effects of ghrelin could be mediated via NPY neurones, the 
unexpected stimulatory effects of ghrelin in vitro could be related to the similarly unexpected effects of NPY that 
we reported previously (6, 7). The discrepancy between the effects obtained both in vitro and in vivo could 
depend on our experimental in vitro conditions. Regional differences in response to ghrelin are suggested by a 
recent electrophysiological study in the arcuate nucleus showing that ghrelin causes neuronal excitation in the 
ventromedial area, possibly through NPY neurones as opposed to inhibition in the ventrolateral area, and 
possibly through pro-opiomelanocortin (POMC) neurones (25). Accordingly, it could be that peripherally 
administered ghrelin activates some neurones that are not reached and/or not activated in our hypothalamic 
expiants. Alternatively, the NPY receptors activated in the in vitro conditions (i.e. the NPY-Y5 subtype as shown 
in this study) could be different from the receptors mediating NPY inhibition of the pituitary-gonadal axis in vivo 
(i.e. the NPY-Y1 and NPY-Y2 receptors) (23, 24, 26). The absence of an effect of NPY and ghrelin when 
incubated with ex-plants obtained at 50 days could suggest a developmental variation in expression of the NPY-
Y5 receptor subtype. As previously shown (6), no effect could be observed with the NPY-Y5 receptor antagonist 
at day 5, whereas an increase of GnRH IPI was observed at 15, 25 and 50 days. Moreover, the hypothalamic 
expiants could not exhibit the inhibitory response to NPY if they do not retain the ult-radian and cyclic patterns 
of NPY discharge governing the basal and cyclic variations in GnRH-LH secretion (22) possibly involved in 
such a response. Whatever the explanation, the physiological or functional significance of data obtained in vitro 
should be considered as limited, particularly when peripheral hormones are used and the data are discordant from 
in vivo observations. However, the reliability of the data obtained in vitro supports the relevance of the in vitro 
paradigm to study the intrahypothalamic mediators involved in peptide effects on GnRH secretion, even if the 
activity of such mediators could not necessarily reflect the in vivo conditions. 
Fig. 2. Effect of anorectic, orexigenic and antagonist peptides on the gonadotrophin-releasing hormone (GnRH) 
interpulse interval using hypothalamic expiants from prepubertal (15 days) and adult (50 days) male rats. Data 
are shown as mean ± SD. The number of expiants in each experiment is given in parentheses. *P < 0.05 versus 
control. CRF, Corticotrophin-releasing factor (CRF); α-MSH, α-melanocyte-stimulating hormone; CART, 
cocaine and amphetamine-regulated transcript; NPY, neuropeptide Y. 
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Thus, we took advantage of the hypothalamic expiant model to study some anorectic or orexigenic neuropeptide 
mediators involved in the effects of leptin and ghrelin. Here, expiants obtained in 15-day-old animals were used 
because GnRH pulse frequency is affected by both leptin and ghrelin at that age whereas only ghrelin results in 
some effects at 50 days. In a previous work, CART was shown to mediate part of the effects of leptin (6). A role 
of the melanocortin system in mediating the effects of leptin is supported by leptin receptor expression in POMC 
neurones in the arcuate nucleus (27). POMC expression and the frequency of action potentials in the POMC 
neurones are stimulated by leptin (28, 29).α-MSH synthesised in POMC neurones binds to the MC3/MC4 
receptors, which mediate a decrease in food intake caused by agonists of MC4-R and leptin (30), with this effect 
being blocked by SHU 9119, a pharmacological MC3/MC4-R antagonist (31). In the present study, α-MSH 
stimulation of pulsatile GnRH secretion is totally prevented using SHU 9119 whereas this antagonist partially 
overcomes the acceleration of pulsatile GnRH secretion caused by leptin. Thus, a pathway involving POMC  
neurones, α-MSH and MC4-receptors partly mediates the control of GnRH secretion by leptin. A direct α-MSH 
stimulation of GnRH neurones is suggested by the synaptic contacts shown between α-MSH-containing 
neurones and GnRH neurones (32) and the expression of functional MC4-R by GT1-cells (33). Other studies 
have provided evidence of melanocortin system involvement in leptin stimulation of GnRH secretion in vivo 
(34). However, in the male ob/ob mouse, the MC4-R agonist MTII has no effect on plasma gonadotrophin levels 
(35). Inactivation or blockade of the MC4-R is unable to alter leptin stimulatory effects on the reproductive axis 
in that mutant mouse (35) or to alter LH secretion in nonmutant rodents (36, 37). The discrepancies between 
these observations may be explained by experimental conditions: acute versus chronic peptide administration, 
steroid environment, in vitro versus in vivo settings. Also, the existence of multiple pathways for the effects of 
leptin on GnRH secretion might account for the absence of any dysfunction in vivo following inactivation of 
MC4-R. The developmental stage may influence the response as discussed below. 
The CRF-containing neurones in the paraventricular nucleus are another target of leptin action in the regulation 
of food intake (38, 39). For example, the CRF1-9 α-helical antagonist prevents the inhibition of feeding by leptin 
(40). In the present study, at 15 days, the frequency of pulsatile GnRH secretion was stimulated by CRF, with 
this effect being prevented by the CRF antagonist α-helical CRF 9-41. CRF acts as an important inhibitory 
neuromodulator of GnRH-LH secretion and appears to be a possible mediator of the inhibitory effect of stress on 
the hypothalamic-pituitary-gonadal axis (41-44). However, CRF does not appear to be a prerequisite for that 
mechanism because the stressor-induced suppression of LH surge occurs in the CRF knockout female mouse 
(45). Thus, depending on experimental conditions, including the steroid environment (46), CRF could result in 
either inhibitory or stimulatory or no effects on GnRH-LH secretion, such as previously discussed for α-MSH. 
Our observation that the increase of pulsatile GnRH secretion induced by leptin is partially prevented by a CRF 
antagonist suggests a mediating pathway involving leptin and CRF-containing neurones in the regulation of 
GnRH secretion. Anatomical connections between CRF terminals and GnRH-secreting neurones have been 
reported (47). Taken together, our previous data and that of the present study indicate that CART-, CRF- and 
POMC-expressing neurones are possible additive and alternative mediators of the effects of leptin on GnRH 
secretion. Such redundant pathways might explain the gonadal disruption in leptin-deficient rodent whereas 
inactivation or blockade of any peptide that mediates the effects of leptin does not affect the reproductive axis in 
vivo. In addition, a direct effect of leptin on GnRH neurones is possible because leptin receptors are expressed in 
GT1-7 immortalised GnRH cells (48). 
Ghrelin is an endogenous ligand for the growth hormone secret-agogue receptors (GHS-R) which are expressed 
in the arcuate nucleus and the ventromedial hypothalamus (49). GHS-R mRNAs are expressed highly in 
NPY/AgRP-neurones and weakly in POMC-neurones. However, a recent study suggested that ghrelin could 
inhibit LH secretion independent of the GHS-R because the unacyl-ated form of the peptide caused such an 
effect (14). The reduction in GnRH pulse frequency reported in the present study after systemic administration of 
ghrelin is consistent with the reduction in LH secretion found in different species (11-14, 50). The involvement 
of NPY in the mediation of the effects of ghrelin on pulsatile GnRH secretion is indicated by the complete 
abolition of the effects of ghrelin by the NPY-Y5 receptor antagonist, consistent with the ghrelin-NPY-NPY-Y5 
receptor pathway operating in the control of food intake (17). An increased expression of CRF mRNA occurs 
after peripheral administration of ghrelin and the ghrelin-induced orexigenic effect in mice is inhibited by a CRF 
antagonist (51). However, our data obtained using a CRF antagonist do not support a connection between ghrelin 
and CRF-expressing neurones in the regulation of pulsatile GnRH secretion. The partial but significant 
prevention by SHU 9119 of the effects of ghrelin on pulsatile GnRH secretion suggested an unexpected link 
between ghrelin and POMC-expressing neurones. Although electrophysiological studies show that ghrelin 
hyperpolarises POMC neurones in the arcuate nucleus, most likely through a NPY effect, a paradoxical ghrelin-
induced depolari-sation of POMC neurones could be due to the effects of AgRP (10). Such a mediating pathway 
was investigated in the present study through the action of AgRP, an endogenous MC3/MC4 receptor antagonist,   
which is synthesized and secreted in the arcuate nucleus and colocalised with NPY neurones (52). Systemically-
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administred AgRP was as effective as ghrelin in reducing the GnRH pulse frequency and a similar effect was 
obtained during incubation with AgRP in vitro. These effects are consistent with the suppression of pulsatile LH 
release after central infusion of AGRP in the monkey (53). Despite the inhibitory effect of AGRP on pulsatile 
GnRH secretion, SHU 9119 had no effects. This could be due to either a more potent action of AGRP than SHU 
9119 on MC3/MC4-receptors or the existence of other AGRP receptors, as already suggested (54). 
The mediation of leptin and the effects of ghrelin could also involve neuropeptides known to be critical for the 
GnRH neurone function such as kisspeptin. Kiss-1 neurones have been shown to express the leptin receptor and 
to be less active in the o6/ob mouse (55). These neurones could thus provide a more direct pathway of leptin 
connexion to the GnRH neurones. However, the Kiss-1 neurones could also be involved in the regulation of the 
effects of ghrelin because the LH secretory response to kisspeptin is reduced by ghrelin (14). 
Because developmental variations in pulsatile GnRH secretion were observed in our model and nutrition-related 
neuropeptides could be involved in the mechanism of sexual maturation, the effects of anorectic and orexigenic 
peptides were compared in immature and adult male rats. After systemic administration at 50 days, leptin no 
longer shows the stimulatory effect seen at 15 days whereas a persistent inhibitory effect is observed with ghrelin 
and AGRP. Consistent with the data obtained in vivo, leptin, α-MSH, CART and CRF show no effects when 
directly incubated in vitro at 50 days as opposed to the effects seen at 15 days. A fully effective endogenous 
level of activity of leptin and mediating neuropeptides in the adult hypothalamus could account for the absence 
of effects of the anorectic neuropeptides at 50 days as opposed to 15 days. In accordance with that concept, 
pulsatile GnRH secretion can be influenced at 50 days by prevention of the effects of endogenous neuropeptides 
using the CRF antagonist and SHU 9119 whereas no effects were observed at 15 days. Because the stimulatory 
effects of α-MSH on pulsatile GnRH secretion disappeared at 50 days, whereas inhibitory effects of SHU9119 
appeared, this suggests that maturation results in increased endogenous stimulation at MC4 receptors. The 
absence of anti-CART AS effects could be explained by a subtotal neutralisation due to insufficient 
concentration of the antiserum. It was interesting to observe a potent and age-independent effect of AgRP, which 
appeared to inhibit GnRH pulse frequency to a similar extent after peripheral administration in the immature and 
adult rat. Thus, the developmental changes in the regulation of GnRH pulse frequency primarily involved the 
anorectic peptides as opposed to the orexigenic peptides. 
In conclusion, an opposite effect of leptin and ghrelin is shown on the frequency of pulsatile GnRH secretion, 
consistent with the pathophysiological observations linking energy balance and reproductive function. Those two 
hormones act through distinct neuromediators, with CART and CRF-expressing neurones being primary targets 
for leptin and NPY-containing neurones for ghrelin. By contrast, the melanocortigenic system appears to be a 
common pathway for mediation of the actions of both leptin and ghrelin. Between prepuberty and adulthood, the 
stimulatory activity of the anorectic mediators appears to increase whereas the inhibitory effects of the 
orexigenic mediators appear to operate both before and after puberty. 
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